GIP / GLP-1 Dual Agonist
Tirzepatide
A dual incretin agonist combining GIP and GLP-1 receptor activity in a single molecule, associated with larger mean body-mass reductions than single-pathway GLP-1 agonists in comparative trials.
Price at Core Power Peptides
50 mg vial · $6.40/mg
Struck-through figure is the supplier's own listed price before its current sale. Prices checked Sep 29, 2026.
Disclosure: links marked “Shop” or “Check price” go to Core Power Peptides, our research-peptide supplier partner. We may earn a commission when you purchase through these links, at no added cost to you. This never changes which compounds we cover or how we describe them.
Mechanism
Co-activates GIP and GLP-1 receptors. The added GIP component appears to improve insulin sensitivity and adipose signaling beyond what GLP-1 activation alone produces, an effect researchers are still mapping in mechanistic detail.
Research focus
- Category
- GIP / GLP-1 Dual Agonist
- Sequence length
- 39 amino acids
- Research status
- Approved analog exists
- Best for
- The dual-agonist most researchers reach for first
Related compounds
Ready to compare pricing across the whole GLP-1 family?
Shop Core Power PeptidesReviewed by the Peptides For Weight Loss editorial team. See our editorial standards and sourcing methodology.